Want to read (4)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group.
Lancet · 2017
Drugging the undruggable RAS: Mission possible?
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ.
Nat Rev Drug Discov · 2014
Coactivator condensation at super-enhancers links phase separation and gene control
Sabari BR, Dall'Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, Abraham BJ, Hannett NM, Zamudio AV, Manteiga JC, Li CH, Guo YE, Day DS, Schuijers J, Vasile E, Malik S, Hnisz D, Lee TI, Cisse II, Roeder RG, Sharp PA, Chakraborty AK, Young RA.
Science · 2018
Phases of A beta-deposition in the human brain and its relevance for the development of AD
Thal DR, Rüb U, Orantes M, Braak H.
Neurology · 2002